# COVID-19 Vaccine Eligibility

The COVID-19 vaccines authorized for use in Canada include: Comirnaty™ (Pfizer-BioNTech) – Adult/Adolescent presentation, Comirnaty™ (Pfizer-BioNTech) – Pediatric presentation, Spikevax™ (Moderna), Vaxzevria™/COVISHIELD (AstraZeneca), and Janssen (Ad26.COV2.S [recombinant]). Refer to the respective product page for product specific information.

## Primary Series

<table>
<thead>
<tr>
<th>Eligibility Criteria</th>
<th>Number of Doses</th>
</tr>
</thead>
</table>
| Pediatric population – 5 to 11 years of age (inclusive) | 2 doses of:  
• Pfizer: 0.2 mL (10 mcg) |
| General population – 12 years of age and older | 2 doses \(^A\) of any:  
• Pfizer: 0.3 mL (30 mcg)  
• Moderna: 0.5 mL (100 mcg)  
• AstraZeneca/COVISHIELD (≥ 18 years of age): 0.5mL  
**OR**  
1 dose:  
• Janssen (≥ 18 years of age): 0.5 mL |
| Moderately to severely immunosuppressed – 12 years of age and older:  
• Have had a solid organ transplant (heart, lung, liver, kidney, pancreas or islet cells, bowel or combination organ transplant).  
• Since January 2020, have received treatment with any anti-CD20 agents (i.e., rituximab, ocrelizumab, ofatumumab, obinutuzumab, ibritumomab, tositumomab).  
• Since January 2020, have been treated with B-cell depleting agents (i.e., epratuzumab, MEDI-551, belimumab, BR3-Fc, AMG-623, atacicept, anti-BR3, alemtuzumab).  
• Since October 2020, have received or are receiving radiation therapy for cancer.  
• Since March 2020, have received or are receiving systemic therapy for solid tumours as well as hematological cancers (including chemotherapy, molecular therapy, immunotherapy, targeted therapies including CAR-T, monoclonal antibodies, hormonal therapy for cancer).  
• Have combined immune deficiencies affecting T-cells, immune dysregulation (particularly familial hemophagocytic lymphohistiocytosis) or type 1 interferon defects (caused by a genetic primary immunodeficiency disorder or secondary to anti-interferon autoantibodies).  
• Since September 2019, have had a bone marrow or stem cell transplant or are still taking immunosuppressant medications related to transplant.  
• Have a moderate to severe primary immunodeficiency which has been diagnosed by an adult or pediatric. | 3 doses \(^A\) of any:  
• Moderna: 0.5 mL (100 mcg)  
(preferentially recommended)  
• Pfizer: 0.3 mL (30 mcg)  
• AstraZeneca/COVISHIELD (≥ 18 years of age): 0.5mL  
* For individuals who received a single dose of Janssen vaccine, a 2-dose primary series is recommended. |

\(^A\) mRNA vaccines are preferred over viral vector vaccines due to the better effectiveness and immunogenicity of mRNA vaccines and the possible adverse effects specifically associated with viral vector vaccines (e.g., Thrombosis with Thrombocytopenia Syndrome [TTS]).
immunologist and requires ongoing immunoglobulin replacement therapy (IVIG or SCIG) or the primary immunodeficiency has a confirmed genetic cause (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).

- On dialysis (hemodialysis or peritoneal dialysis) or have stage 5 chronic kidney disease (eGFR <15 mL/min) or have glomerulonephritis and receiving steroid treatment.
- Prior AIDS defining illness or CD4 count ≤ 200/mm³ or CD4 fraction ≤ 15% or detectable plasma viral load since January 2021 or HIV infection and ≥ 65 years old or perinatally acquired HIV infection.
- Have taken significantly immunosuppressing drugs or treatments including at risk biologics, steroids and other agents since December 15, 2020. \(^B\)

### Booster Dose \(^C\)

<table>
<thead>
<tr>
<th>Eligibility Criteria</th>
<th>Number of Doses</th>
</tr>
</thead>
</table>
| - Residents of long term care (LTC), assisted living and independent living facilities, and alternate level of care clients awaiting placement in LTC.  
  - Individuals 70 years of age and older.                                             | 1 dose – at least 6 months after completion of the primary series:  
  - Pfizer: 0.3 mL (30 mcg)  
  - Moderna: 0.5 mL (100 mcg)                                                         |
| - Individuals 18-69 years of age receiving long-term home support.                   | 1 dose – at least 6 months after completion of the primary series:  
  - Pfizer: 0.3 mL (30 mcg)  
  - Moderna: 0.25 mL (50 mcg)                                                         |
| - Indigenous peoples 18-69 years of age.                                             |                                                                                  |
| - Individuals 18-69 years of age in rural and remote communities.                   |                                                                                  |
| - Health care workers 18-69 years of age who received their second dose on or before March 15, 2021. |                                                                                  |
| - Individuals 18-69 years of age who received AstraZeneca/COVISHIELD for both dose 1 and 2. |                                                                                  |
| - Individuals 18-69 years of age who are vulnerable or in congregate settings in outbreaks at the direction of the Medical Health Officer. |                                                                                  |

\(^B\) A list of these medications can be found on the [government of B.C. website](https://www.gov.bc.ca).  
\(^C\) The booster dose is authorized for individuals 18 years of age and older.